Literature DB >> 21266724

Lessons from type I interferons in ulcerative colitis.

Arthur Kaser1, Richard S Blumberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21266724      PMCID： PMC4592161          DOI： 10.1136/gut.2010.229138

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  15 in total

1.  Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells.

Authors:  Frank Heller; Ivan J Fuss; Edward E Nieuwenhuis; Richard S Blumberg; Warren Strober
Journal:  Immunity       Date:  2002-11       Impact factor: 31.745

2.  Delineation of a CD1d-restricted antigen presentation pathway associated with human and mouse intestinal epithelial cells.

Authors:  Yvonne van de Wal; Nadia Corazza; Matthieu Allez; Lloyd F Mayer; Hideki Iijima; Mark Ryan; Steven Cornwall; Dominique Kaiserlian; Robert Hershberg; Yasuhiko Koezuka; Sean P Colgan; Richard S Blumberg
Journal:  Gastroenterology       Date:  2003-05       Impact factor: 22.682

3.  Suppression of inflammation in ulcerative colitis by interferon-β-1a is accompanied by inhibition of IL-13 production.

Authors:  Peter J Mannon; Ronald L Hornung; Zhiqiong Yang; Chuli Yi; Catherine Groden; Julia Friend; Michael Yao; Warren Strober; Ivan J Fuss
Journal:  Gut       Date:  2010-10-22       Impact factor: 23.059

4.  Interferon-beta-1a for the treatment of steroid-refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trial.

Authors:  Eugen Musch; Tilo Andus; Wolfgang Kruis; Andreas Raedler; Martina Spehlmann; Stefan Schreiber; Bernd Krakamp; Mouhamad Malek; Helmut Malchow; Filip Zavada; Gerhard Engelberg Feurle
Journal:  Clin Gastroenterol Hepatol       Date:  2005-06       Impact factor: 11.382

5.  Expression of a nonpolymorphic MHC class I-like molecule, CD1D, by human intestinal epithelial cells.

Authors:  R S Blumberg; C Terhorst; P Bleicher; F V McDermott; C H Allan; S B Landau; J S Trier; S P Balk
Journal:  J Immunol       Date:  1991-10-15       Impact factor: 5.422

6.  Differential regulation of interleukin 4 and interleukin 13 production by interferon alpha.

Authors:  A Kaser; C Molnar; H Tilg
Journal:  Cytokine       Date:  1998-02       Impact factor: 3.861

Review 7.  Inflammatory bowel disease.

Authors:  Arthur Kaser; Sebastian Zeissig; Richard S Blumberg
Journal:  Annu Rev Immunol       Date:  2010       Impact factor: 28.527

8.  Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-la in moderately active ulcerative colitis.

Authors:  C Pena-Rossi; S Schreiber; G Golubovic; A Mertz-Nielsen; J Panes; D Rachmilewitz; M J Shieh; V I Simanenkov; D Stanton; H Graffner
Journal:  Aliment Pharmacol Ther       Date:  2008-09-15       Impact factor: 8.171

9.  Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis.

Authors:  Ivan J Fuss; Frank Heller; Monica Boirivant; Francisco Leon; Masaru Yoshida; Stefan Fichtner-Feigl; Zhiqiong Yang; Mark Exley; Atsushi Kitani; Richard S Blumberg; Peter Mannon; Warren Strober
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

10.  A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis.

Authors:  H Tilg; H Vogelsang; O Ludwiczek; H Lochs; A Kaser; J-F Colombel; H Ulmer; P Rutgeerts; S Krüger; A Cortot; G D'Haens; M Harrer; C Gasche; F Wrba; I Kuhn; W Reinisch
Journal:  Gut       Date:  2003-12       Impact factor: 23.059
View more
  2 in total

1.  Unraveling the autoimmune translational research process layer by layer.

Authors:  Richard S Blumberg; Bonnie Dittel; David Hafler; Matthias von Herrath; Frank O Nestle
Journal:  Nat Med       Date:  2012-01-06       Impact factor: 53.440

2.  Infection of specific strains of Streptococcus mutans, oral bacteria, confers a risk of ulcerative colitis.

Authors:  Ayuchi Kojima; Kazuhiko Nakano; Koichiro Wada; Hirokazu Takahashi; Kazufumi Katayama; Masato Yoneda; Takuma Higurashi; Ryota Nomura; Kazuya Hokamura; Yoshinori Muranaka; Nobuyuki Matsuhashi; Kazuo Umemura; Yoshinori Kamisaki; Atsushi Nakajima; Takashi Ooshima
Journal:  Sci Rep       Date:  2012-03-26       Impact factor: 4.379
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.